ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Vice President - Operations. Mr. Gopalkrishnan will be responsible for managing ERBA Diagnostics’ daily operations and will be based in its Miami headquarters.
Kevin Clark, President and Chief Executive Officer of ERBA Diagnostics, said, “Mohan Gopalkrishnan’s appointment as V.P. Operations is a welcome strengthening of our management team. With a lifelong career in the healthcare industry, we expect that Mohan’s experience will strengthen the management team and improve efficiencies to help the company reach its full potential.”
Mr. Gopalkrishnan, age 57, has over 30 years of experience in the diagnostics and medical devices industry. He started his career with Boehringer Mannheim in India and spent the last 15 years with Becton Dickinson, starting as a Business Leader for Medical Devices in India and then as ERP Leader for Asia and Business Director for Asia based in Singapore and, during the most recent five years, in the U.S. as Senior Director with global responsibility for a $550 million franchise.
Mr. Clark continued, “Mohan Gopalkrishnan has demonstrated that he is an experienced business leader with a consistent track record of building sustainable businesses across countries, regions and global platforms with strong strategic capabilities balanced with intense execution focus to drive growth through customer centric product and services innovation. We are confident that Mohan will be a catalyst of change for driving and sustaining growth and developing talent within our organization.”
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (
), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its legacy subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe) and ImmunoVision, Inc. (U.S.) – and through its recently acquired subsidiaries – Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.) and Drew Scientific Limited Co. (Europe).
Safe Harbor Statement
Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, Inc., including, without limitation:
the risks and uncertainties associated with ERBA Diagnostics’ business strategies, including, without limitation, the risk Mr. Gopalkrishnan’s appointment may not be a catalyst for change, may not have a positive impact on its success or that such business strategies may not otherwise be successful or lead to ERBA Diagnostics achieving improved efficiencies, sales or operating results; the risk that ERBA Diagnostics may not be able to achieve its goals or grow, develop or sustain its business; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.
In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in ERBA Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.